MIRA Pharmaceuticals, Inc.

DB:K6S Stock Report

Market Cap: €27.5m

MIRA Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

MIRA Pharmaceuticals's earnings have been declining at an average annual rate of -52.9%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually.

Key information

-52.9%

Earnings growth rate

-103.1%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth raten/a
Return on equity-576.1%
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How MIRA Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:K6S Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-1373
31 Mar 240-1272
31 Dec 230-1272
30 Sep 230-852
30 Jun 230-642
31 Mar 230-752
31 Dec 220-752
31 Mar 220-421
31 Dec 210-211

Quality Earnings: K6S is currently unprofitable.

Growing Profit Margin: K6S is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: K6S is unprofitable, and losses have increased over the past 5 years at a rate of 52.9% per year.

Accelerating Growth: Unable to compare K6S's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: K6S is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).


Return on Equity

High ROE: K6S has a negative Return on Equity (-576.14%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies